Expert Interview
Discussing the upcoming PDUFA for Axsome Therapeutics' AXS-05 (Auvelity) for Alzheimer's Disease Agitation (ADA)
Ticker(s): AXSM, OTSKY, HLBBFInstitution: University of Rochester
- Neurologist and Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program.
- Currently manages 150 patients with Alzheimer's Disease.
- Site PI for studies with solanezumab, gantenerumab, lecanemab, aducanemab, donanemab, semorinemab, pepinemab, AL-002, ATH-1017, and simufilam. Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia.
How many Alzheimer's Disease patients do you manage?
Added By: wilson_adminHow big of an issue is managing ADA in practice?
Added By: wilson_adminDo you think Auvelity is likely to get the sNDA approved?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
